Your browser doesn't support javascript.
loading
Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21.
Hamdi, Yosr; Soucy, Penny; Adoue, Véronique; Michailidou, Kyriaki; Canisius, Sander; Lemaçon, Audrey; Droit, Arnaud; Andrulis, Irene L; Anton-Culver, Hoda; Arndt, Volker; Baynes, Caroline; Blomqvist, Carl; Bogdanova, Natalia V; Bojesen, Stig E; Bolla, Manjeet K; Bonanni, Bernardo; Borresen-Dale, Anne-Lise; Brand, Judith S; Brauch, Hiltrud; Brenner, Hermann; Broeks, Annegien; Burwinkel, Barbara; Chang-Claude, Jenny; Couch, Fergus J; Cox, Angela; Cross, Simon S; Czene, Kamila; Darabi, Hatef; Dennis, Joe; Devilee, Peter; Dörk, Thilo; Dos-Santos-Silva, Isabel; Eriksson, Mikael; Fasching, Peter A; Figueroa, Jonine; Flyger, Henrik; García-Closas, Montserrat; Giles, Graham G; Goldberg, Mark S; González-Neira, Anna; Grenaker-Alnæs, Grethe; Guénel, Pascal; Haeberle, Lothar; Haiman, Christopher A; Hamann, Ute; Hallberg, Emily; Hooning, Maartje J; Hopper, John L; Jakubowska, Anna; Jones, Michael.
Afiliação
  • Hamdi Y; Genomics Center, Centre Hospitalier Universitaire de Québec Research Center, Laval University, Quebec, Canada.
  • Soucy P; Genomics Center, Centre Hospitalier Universitaire de Québec Research Center, Laval University, Quebec, Canada.
  • Adoue V; Institut National de la Santé et de la Recherche Médicale U1043, Toulouse, France.
  • Michailidou K; Centre National de la Recherche Scientifique, Toulouse, France.
  • Canisius S; Université de Toulouse, Université Paul Sabatier, Centre de Physiopathologie de Toulouse Purpan, Toulouse, France.
  • Lemaçon A; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Droit A; Department of Electron Microscopy/Molecular Pathology, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
  • Andrulis IL; Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands.
  • Anton-Culver H; Centre de Recherche du CHU de Québec - Université Laval, Faculté de Médecine, Département de Médecine Moléculaire, Université Laval, Quebec, Canada.
  • Arndt V; Centre de Recherche du CHU de Québec - Université Laval, Faculté de Médecine, Département de Médecine Moléculaire, Université Laval, Quebec, Canada.
  • Baynes C; Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada.
  • Blomqvist C; Department of Molecular Genetics, University of Toronto, Toronto, Canada.
  • Bogdanova NV; Department of Epidemiology, University of California Irvine, Irvine, CA, USA.
  • Bojesen SE; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany.
  • Bolla MK; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
  • Bonanni B; Department of Oncology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
  • Borresen-Dale AL; Department of Radiation Oncology, Hannover Medical School, Hannover, Germany.
  • Brand JS; Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
  • Brauch H; Copenhagen General Population Study, Herlevand Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
  • Brenner H; Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
  • Broeks A; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Burwinkel B; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Chang-Claude J; Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia, Milan, Italy.
  • Couch FJ; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Cox A; Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.
  • Cross SS; University of Tübingen, Tübingen, Germany.
  • Czene K; German Cancer Consortium, German Cancer Research Center, Heidelberg, Germany.
  • Darabi H; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany.
  • Dennis J; German Cancer Consortium, German Cancer Research Center, Heidelberg, Germany.
  • Devilee P; Division of Preventive Oncology, German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany.
  • Dörk T; Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands.
  • Dos-Santos-Silva I; Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany.
  • Eriksson M; Molecular Epidemiology Group, German Cancer Research Center, Heidelberg, Germany.
  • Fasching PA; Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
  • Figueroa J; University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • García-Closas M; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Giles GG; Sheffield Cancer Research, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
  • Goldberg MS; Academic Unit of Pathology, Department of Neuroscience, University of Sheffield, Sheffield, UK.
  • González-Neira A; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Grenaker-Alnæs G; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Guénel P; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Haeberle L; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
  • Haiman CA; Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
  • Hamann U; Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
  • Hallberg E; Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
  • Hooning MJ; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Hopper JL; Department of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  • Jakubowska A; David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, CA, USA.
  • Jones M; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh, UK.
Oncotarget ; 7(49): 80140-80163, 2016 Dec 06.
Article em En | MEDLINE | ID: mdl-27792995
ABSTRACT
There are significant inter-individual differences in the levels of gene expression. Through modulation of gene expression, cis-acting variants represent an important source of phenotypic variation. Consequently, cis-regulatory SNPs associated with differential allelic expression are functional candidates for further investigation as disease-causing variants. To investigate whether common variants associated with differential allelic expression were involved in breast cancer susceptibility, a list of genes was established on the basis of their involvement in cancer related pathways and/or mechanisms. Thereafter, using data from a genome-wide map of allelic expression associated SNPs, 313 genetic variants were selected and their association with breast cancer risk was then evaluated in 46,451 breast cancer cases and 42,599 controls of European ancestry ascertained from 41 studies participating in the Breast Cancer Association Consortium. The associations were evaluated with overall breast cancer risk and with estrogen receptor negative and positive disease. One novel breast cancer susceptibility locus on 4q21 (rs11099601) was identified (OR = 1.05, P = 5.6x10-6). rs11099601 lies in a 135 kb linkage disequilibrium block containing several genes, including, HELQ, encoding the protein HEL308 a DNA dependant ATPase and DNA Helicase involved in DNA repair, MRPS18C encoding the Mitochondrial Ribosomal Protein S18C and FAM175A (ABRAXAS), encoding a BRCA1 BRCT domain-interacting protein involved in DNA damage response and double-strand break (DSB) repair. Expression QTL analysis in breast cancer tissue showed rs11099601 to be associated with HELQ (P = 8.28x10-14), MRPS18C (P = 1.94x10-27) and FAM175A (P = 3.83x10-3), explaining about 20%, 14% and 1%, respectively of the variance inexpression of these genes in breast carcinomas.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cromossomos Humanos Par 4 / Neoplasias da Mama / Biomarcadores Tumorais / Polimorfismo de Nucleotídeo Único Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans País/Região como assunto: America do norte / Europa Idioma: En Revista: Oncotarget Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cromossomos Humanos Par 4 / Neoplasias da Mama / Biomarcadores Tumorais / Polimorfismo de Nucleotídeo Único Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans País/Região como assunto: America do norte / Europa Idioma: En Revista: Oncotarget Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Canadá
...